Results 121 to 130 of about 67,431 (260)

Imatinib-induced pseudoporphyria

, 2009
P>Imatinib, a synthetic tyrosine kinase inhibitor, is used as first-line therapy for chronic myeloid leukaemia. Imatinib treatment is associated with a variety of adverse effects, most of which are mild to moderate and generally abate after the first ...
Vos - Kardaun, Sylvia, Timmer-de Mik, L., Bousema, M.T., Hayes, D., Kramer, M. H. H., Kardaun, S.H., Hayes, D. P., Bousema, M. T., Kramer, M.H.H.   +8 more
core   +1 more source

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate

, 2007
The BCR-ABL fusion gene product is a constitutively activated tyrosine kinase, which is fundamental in the pathogenesis of chronic myeloid leukemia (CML).
Wei, Yuan
core  

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy‐Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman, Tadi Hondonga, Alison Berry, Caitlin Elgarten, Jason Freedman, Katelyn Oranges, Sara McDonough, Caroline Diorio, L. Lee Dupuis   +8 more
wiley   +1 more source

Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity

, 2015
Gregory Marslin,1 Ann Mary Revina,2,3 Vinoth Kumar Megraj Khandelwal,4 Krishnamoorthy Balakumar,5 Jose Prakash,6 Gregory Franklin,1,* Caroline J Sheeba2,3,7,*1AgroBioPlant Group, Centre for the Research and Technology of Agro-Environment and Biological ...
Balakumar K, Franklin G, Sheeba CJ, Revina AM, Khandelwal VKM, Prakash J, Marslin G   +6 more
core  

The use of imatinib in the treatment of inoperable dermatofibrosarcoma protuberans in the area of the shoulder joint

, 2014
Introduction. Dermatofibrosarcoma protuberans (DFSP) is a rare sarcoma of the skin and subcutaneous tissue. The most common clinical problem is its local recurrence. The therapeutic procedure of choice is radical surgery.
Elżbieta Nowara, Joanna Huszno, Danuta Starzyczny-Słota   +2 more
core   +1 more source

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope

International Journal of Laboratory Hematology, EarlyView.
Paige Muir, Mohammad Bahmanyar, Hamish Nicolson, Hayley Merkeley   +3 more
wiley   +1 more source

Technoeconomic and sustainability analysis of batch and continuous crystallization for pharmaceutical manufacturing

AIChE Journal, Volume 72, Issue 7, July 2026.
Abstract In pharmaceutical industries, continuous manufacturing methods have already been well established to improve productivity and process intensification. However, to better understand the trade‐offs of continuous crystallizers over the existing batch production systems, a robust technoeconomic cost and sustainability analysis is necessary to ...
Jungsoo Rhim, Zoltan K. Nagy
wiley   +1 more source

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia

, 2012
Yusuf Baran,1 Guray Saydam21Department of Molecular Biology and Genetics, Izmir Institute of Technology, Izmir, Turkey; 2Department of Hematology, School of Medicine, Ege University, Izmir, TurkeyAbstract: Chronic myeloid leukemia (CML) is a malignant ...
Saydam G, Baran Y
core